ECM
LCTX icon

ExodusPoint Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

ExodusPoint Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,157
Closed -$33.4K – 1841
2026
Q1 		$33.4K Sell
21,157
-160,537
-88% -$271K ﹤0.01% 1467
2025
Q4 		$303K Buy
+181,694
New +$314K ﹤0.01% 1310
2025
Q3 		– Sell
-19,149
Closed -$17K – 1796
2025
Q2 		$17K Buy
+19,149
New +$11.4K ﹤0.01% 1387
2023
Q2 		– Sell
-32,143
Closed -$48K – 2072
2023
Q1 		$48K Buy
+32,143
New +$44.9K ﹤0.01% 1667
2022
Q1 		– Sell
-12,142
Closed -$30K – 2454
2021
Q4 		$30K Buy
+12,142
New +$28.4K ﹤0.01% 2069
2021
Q2 		– Sell
-334,197
Closed -$785K – 2599
2021
Q1 		$785K Sell
334,197
-473,415
-59% -$1.14M 0.01% 1064
2020
Q4 		$1.42M Buy
807,612
+792,095
+5,105% +$1.11M 0.01% 688
2020
Q3 		$15K Buy
15,517
+2,293
+17% +$2.02K ﹤0.01% 1673
2020
Q2 		$12K Buy
+13,224
New +$11.6K ﹤0.01% 1715

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

ExodusPoint Capital Management's LCTX Position: Q2 2026 in Review

ExodusPoint Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 21,157 shares — an estimated $33.4K sold.

ExodusPoint Capital Management first reported a position in LCTX in Q2 2020 and held it in 9 quarters. The position peaked at $1.42M in Q4 2020. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • ExodusPoint Capital Management reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ExodusPoint Capital Management sold 21,157 Lineage Cell Therapeutics shares in Q2 2026, an estimated $33.4K.
  • ExodusPoint Capital Management first reported a position in Lineage Cell Therapeutics in Q2 2020 and held it in 9 quarters.
  • ExodusPoint Capital Management's Lineage Cell Therapeutics position peaked at $1.42M in Q4 2020.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.